Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 14 of 14 publications.

George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w

Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3

Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x

Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4

Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A. Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hered Cancer Clin Pract. 2020 Sep 29;18(20). doi: 10.1186/s13053-020-00152-z

Paquette M, Franca LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry. Am J Cardiol. 2020 Feb 1;125(3):383-91. doi: 10.1016/j.amjcard.2019.10.047

Adelborg K, Rasmussen TB, Norrelund H, Layton JB, Sorensen HT, Christiansen CF. Cardiovascular outcomes and all-cause mortality following measurement of endogenous testosterone levels. Am J Cardiol. 2019 Jun 1;123(11):1757-64. doi: 10.1016/j.amjcard.2019.02.042

Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, Marsal JR, Barbanti M, Cote M, Rodes-Cabau J. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol. 2018 Jul 15;122(2):310-5. doi: 10.1016/j.amjcard.2018.04.006

Camplain R, Kucharska-Newton A, Keyserling TC, Layton JB, Loehr L, Heiss G. Incidence of heart failure observed in emergency departments, ambulatory clinics, and hospitals. Am J Cardiol. 2018 Jun 1;121(11):1328-35. doi: 10.1016/j.amjcard.2018.02.014

Layton JB, Kshirsagar AV, Simpson, Jr RJ, Pate V, Jonsson Funk M, Sturmer T, Brookhart MA. Effect of statin use on acute kidney injury risk following coronary artery bypass grafting. Am J Cardiol. 2013 Mar 15;111(6):823-8. doi: 10.1016/j.amjcard.2012.11.047

Hayek S, Canepa Escaro FC, Sattar A, Gamalski S, Wells KE, Divine G, Ahmedani BK, Lanfear DE, Pladevall M, Williams LK. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol. 2013 Feb 1;111(4):532-9.

Ribera A, Ferreira-Gonzalez I, Marsal JR, Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Inigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Guemez L, Garcia-Del-Blanco B, Marti G, Garcia-Dorado D. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents. Am J Cardiol. 2011 Nov 1;108(9):1225-31. doi: 10.1016/j.amjcard.2011.06.036

Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (The Framingham Offspring Study). Am J Cardiol. 2003 Feb 15;91(4):485-8.